Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

The supplemental application is for the addition of extended dosing intervals (up to every 24 weeks) of EYLEA HD injection 8 mg across all approved indications. The FDA disagreed with Regeneron ...

Total revenues decreased 4% year over year to $3 billion due to lower sales of lead drug Eylea. Revenues also missed the Zacks Consensus Estimate of $3.27 billion. Sales of oncology drug ...

In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss; Eylea HD saw increased volume. Don’t miss this list of 10 overlooked stocks—including one paying a 9% ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

(Reuters) -Regeneron’s first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators ...

U.S. sales of Eylea, jointly developed with Bayer, fell 26% in the first quarter to $1.04 billion. First-quarter revenue was $3.03 billion, below expectations of $3.27 billion.

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied ...